Figure 4From: Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgiaMaintenance of sodium oxybate therapeutic response in open-label extension study for patients with at least 12 months of sodium oxybate exposure ( n = 210). *SF-36 PCS is reported for weeks 14, 18, 38 and 42. FIQ, Fibromyalgia Impact Questionnaire; SEM, standard error of the mean; SF-36 PCS, 36-item short-form health survey physical component summary; VAS, visual analog scale.Back to article page